Cognition Therapeutics Inc (CGTX) stock
CGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.63−0.01 (-1.39%)
Close on Nov 17, 2026Market cap $59.90MP/E –Yield –
Cognition Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Cognition Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $26.14M, down 37.5% year over year. For fiscal 2025 it was $37.19M, down 10.8% from the year before. The highest annual figure on record is $41.68M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.19M | -10.8% |
| FY2024 | Dec 31, 2024 | $41.68M | +12.0% |
| FY2023 | Dec 31, 2023 | $37.20M | +22.7% |
| FY2022 | Dec 31, 2022 | $30.32M | +63.3% |
| FY2021 | Dec 31, 2021 | $18.57M | +44.1% |
| FY2020 | Dec 31, 2020 | $12.89M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.10M | -55.6% |
| Q1 FY2026 | Mar 31, 2026 | $6.12M | -43.3% |
| Q4 FY2025 | Dec 31, 2025 | $11.15M | +36.7% |
| Q3 FY2025 | Sep 30, 2025 | $3.77M | -66.9% |
| Q2 FY2025 | Jun 30, 2025 | $11.48M | -0.8% |
| Q1 FY2025 | Mar 31, 2025 | $10.79M | +2.2% |
| Q4 FY2024 | Dec 31, 2024 | $8.15M | -29.7% |
| Q3 FY2024 | Sep 30, 2024 | $11.39M | -2.4% |
| Q2 FY2024 | Jun 30, 2024 | $11.58M | +36.2% |
| Q1 FY2024 | Mar 31, 2024 | $10.55M | +94.3% |
| Q4 FY2023 | Dec 31, 2023 | $11.60M | +80.1% |
| Q3 FY2023 | Sep 30, 2023 | $11.67M | +41.1% |
| Q2 FY2023 | Jun 30, 2023 | $8.50M | -6.6% |
| Q1 FY2023 | Mar 31, 2023 | $5.43M | -16.7% |
| Q4 FY2022 | Dec 31, 2022 | $6.44M | +15.6% |
| Q3 FY2022 | Sep 30, 2022 | $8.27M | +125.0% |
| Q2 FY2022 | Jun 30, 2022 | $9.10M | +85.9% |
| Q1 FY2022 | Mar 31, 2022 | $6.52M | +47.1% |
| Q4 FY2021 | Dec 31, 2021 | $5.57M | +69.5% |
| Q3 FY2021 | Sep 30, 2021 | $3.68M | +8.1% |
| Q2 FY2021 | Jun 30, 2021 | $4.89M | – |
| Q1 FY2021 | Mar 31, 2021 | $4.43M | – |
| Q4 FY2020 | Dec 31, 2020 | $3.29M | – |
| Q3 FY2020 | Sep 30, 2020 | $3.40M | – |
See a number that looks wrong?